Benchmark Holdings plc successfully executed a strategic transition following the multi-million-pound sale of its Benchmark Genetics division to Novo Holdings, subsequently initiating comprehensive plans to delist its ordinary shares from public stock exchanges. The board of directors elected to re-register the corporate entity as a private limited company, citing that the ongoing regulatory burdens, legal expenses, and administrative costs of maintaining public market listings on AIM and Euronext Oslo Growth outweighed the benefits for its remaining scaled operations.